Michio Hirano is a neurologist at the Columbia University Medical Center.He specializes in neuroscience.He is a member of Division of Neuromuscular Disorders and the H. Houston Merritt Clinical Research Center.
Michio Hirano, MD, is a Harvard-trained neurologist who is a professor at the prestigious Columbia University.He first received his BA from Harvard College, before completing his Master’s Degree from Albert Einstein College of Medicine.His research focuses on mitochondrial diseases - a group of disorders caused by dysfunctional mitochondria which fail to produce enough energy for cell or organ function - and his areas of expertise include neuromuscular disease, myopathy and muscular dystrophy.He has authored or co-authored scores of scientific articles in his specialty published in the peer reviewed medical literature.
Events - Primer's event detection algorithm clusters and summarizes multiple documents describing real-world events.
Mentions - Mentions are snippets of text that map to a person.
Docs - The number of documents that match to a person in Primer's corpus of news articles.
Full tech explainer here.
To update Wikipedia with this information, visit the page for the subject above.
the Columbia University Medical Center
The meeting, which lasted more than five hours, was also attended by medics from the London hospital. The little boy’s parents Chris Gard and Connie Yates want a judge to rule that their son, who suffers from a rare genetic condition and has brain damage, should be allowed to undergo a therapy trial overseen by Dr Hirano in the US. Dr Hirano, who has claimed an experimental drug could potentially save Charlie, attended Tuesday’s meeting with a second international expert who is subject to media reporting restrictions. On Monday Dr Hirano was given full access to Charlie’s medical records and hospital and clinical facilities, including diagnostic images, for four and a half hours.
The U.S. physician who sought to provide an experimental treatment to 11-month-old Charlie Gard denied having any financial interest in the therapy Wednesday, according to The Telegraph. Dr. Hirano proposed Charlie undergo nucleoside bypass therapy, which he claimed had a small chance of improving some of Charlie's symptoms. "I became involved in Charlie's case when I was contacted by his parents, and I subsequently agreed to speak with his doctors to discuss whether an experimental therapy being developed in my lab could provide meaningful clinical improvement in Charlie's condition," Dr. Hirano said in a statement. Charlie's physicians at the Great Ormond Street Hospital for Children in London said in a statement July 24 they were "surprise and disappoint" to learn Dr. Hirano "retain a financial interest in some of the NBT compounds he proposed prescribing for Charlie," and that … he had not read Charlie's contemporaneous medical records or viewed Charlie's brain imaging or read all of the second opinions about Charlie's condition … or even read the judge's decision."